Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) have been assigned a consensus rating of “Buy” from the thirteen brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $28.88.

Several research firms have commented on ATRA. Zacks Investment Research cut shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Stifel Nicolaus lowered their price objective on shares of Atara Biotherapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Canaccord Genuity lifted their price objective on shares of Atara Biotherapeutics from $70.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday. Evercore ISI began coverage on shares of Atara Biotherapeutics in a research note on Tuesday, June 30th. They issued an “outperform” rating on the stock. Finally, Mizuho began coverage on shares of Atara Biotherapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $38.00 price objective on the stock.

Atara Biotherapeutics stock opened at $15.64 on Friday. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -3.12 and a beta of 2.12. The company’s 50-day moving average price is $13.06 and its two-hundred day moving average price is $11.36. Atara Biotherapeutics has a 52 week low of $4.52 and a 52 week high of $19.36.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.21) by $0.07. On average, equities research analysts anticipate that Atara Biotherapeutics will post -4.51 earnings per share for the current year.

In other news, CEO Pascal Touchon sold 12,135 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $12.92, for a total value of $156,784.20. Following the transaction, the chief executive officer now directly owns 264,844 shares of the company’s stock, valued at $3,421,784.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 20,116 shares of company stock worth $253,274. 4.30% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Atara Biotherapeutics by 66.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,485 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,786 shares during the period. Bank of Montreal Can acquired a new stake in shares of Atara Biotherapeutics during the second quarter worth approximately $70,000. Point72 Hong Kong Ltd acquired a new stake in shares of Atara Biotherapeutics during the second quarter worth approximately $78,000. Marshall Wace LLP acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth approximately $284,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Atara Biotherapeutics by 35.8% during the first quarter. SG Americas Securities LLC now owns 10,828 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 2,855 shares during the period.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: Yield Curve

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.